FIELD: medicine; ophthalmology.
SUBSTANCE: invention relates to the field of medicine, namely to ophthalmology; it is intended for the treatment of neovascular age-related macular degeneration (hereinafter – nAMD) in a patient. A method for the treatment of nAMD includes the administration to a patient of three individual doses of VEGF antagonist with four-week intervals and, after that, administration to a patient of an additional dose of VEGF antagonist once every 12 weeks and/or every 8 weeks, where each dose of VEGF antagonist is at least 3 mg.
EFFECT: use of the invention allows for greater improvement of visual acuity and prolongated therapeutic effect.
16 cl, 1 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING EYE DISEASES | 2015 |
|
RU2722643C2 |
| METHODS FOR TREATMENT OF EYE DISEASES | 2019 |
|
RU2776850C2 |
| APPLICATION OF ANTAGONIST VEGF IN TREATMENT OF CHORIORETINAL NEOVASCULAR DISTURBANCES AND DISORDERS OF PENETRATION IN PEDIATRIC PATIENTS | 2014 |
|
RU2676274C2 |
| USE OF SIROLIMUS FOR TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH PERSISTENT EDEMA | 2017 |
|
RU2765728C2 |
| LIPOSOME FORMULATIONS | 2013 |
|
RU2680096C2 |
| LIPOSOMAL PREPARATIONS | 2013 |
|
RU2817350C2 |
| NUTRICEUTICAL OPHTHALMOLOGICAL COMPOSITION FOR TREATMENT OF RETINAL PATHOLOGIES WITH A NEOVASCULAR COMPONENT | 2019 |
|
RU2806096C2 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF NEOVASCULAR FORM OF AMD | 2022 |
|
RU2788103C1 |
| INTEGRIN RECEPTOR ANTAGONISTS AND USE THEREOF | 2012 |
|
RU2721907C2 |
| USE OF VEGF ANTAGONIST FOR TREATING RETINOPATHY OF PREMATURITY | 2014 |
|
RU2676303C2 |
